10:11 AM EST - Aeterna Zentaris Inc : announced that it has successfully reached a key milestone in the non-clinical development of its live recombinant prostate cancer vaccine candidate, AEZS-120, for oral administration. Aeterna Zentaris Inc
shares T.AEZ are trading up $0.03 at $2.13.
